Erasca, Inc. (ERAS) saw its stock price soar 5.12% during intraday trading on Friday, marking a significant upward movement for the biopharmaceutical company.
The surge appears to be driven by a series of positive analyst actions reported pre-market. Mizuho raised its price target on Erasca to $19 from $16 while maintaining an Outperform rating. Separately, H.C. Wainwright & Co. maintained its Buy rating on the stock and significantly increased its price target to $20 from $15. These bullish stances from analysts likely provided the catalyst for the stock's strong performance at the market open.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments